Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mycovia Pharmaceuticals, Inc.

http://www.mycovia.com

Latest From Mycovia Pharmaceuticals, Inc.

Keeping Track: Mycovia Vivjoa, BMS Camzyos Approvals Bring FDA’s 2022 Novel Drug Tally To 12

US FDA closed out the month of April with two new molecular entity approvals that address underserved markets but carry some safety concerns.

US FDA Performance Tracker Drug Review

Scynexis Data Show Brexafemme Prevents VVC Recurrence

Phase III data showed that the first-in-class oral antifungal can prevent recurrence of vaginal yeast infections, a potentially valuable label addition to the current indication for acute treatment.

Clinical Trials Drug Approval Standards

Scynexis’s Brexafemme Label-Expansion Plan Focused On Invasive Candidiasis

Scynexis sees a $300m-$400m commercial opportunity for the supplemental indication. A new therapeutic option is needed for oral step-down therapy because many Candida infections are resistant to oral fluconazole.

Business Strategies Commercial

Scynexis Prepares To Launch Brexafemme In Vaginal Yeast Infections, Priced At $475

The first-in-class, novel antifungal for vaginal yeast infections will enter a genericized market, but also one with strong demand for better therapeutic options.

Business Strategies Launches
See All

Company Information

UsernamePublicRestriction

Register